UNSPSC 51113301: Carboquone

This classification denotes an ethylenimine compound with the molecular formula C15H19N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1CB0HBT12C, chemically known as 2,5-cyclohexadiene-1,4-dione, 2,5-bis(1-aziridinyl)-6 (2-hydroxy-1-methoxyethyl)-3-methyl-, carbamate but more generally known as carboquone, which bears US NIH Compound Identifier 2569. European Medicines Agency schedules Carboquone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06616MIG.

UNSPSC 51113301 Carboquone, a Commodity code, encompasses pharmaceutical products sourced through state and local procurement channels, though recent activity under this specific code is limited. The Texas Health and Human Services Commission issued a Request for Information (RFI) on April 3, 2026 (HHS0017013) to explore vendor capabilities for a Therapeutic Pharmacy Initiative focused on direct-to-manufacturer prescription relationships that would bypass traditional pharmacy benefit managers and group purchasing organizations. The RFI seeks vendor experience with direct contracting for self-insured employers and government health plans, capacity to negotiate net pricing models without rebates, and ability to implement value-based or outcomes-based agreements. This preliminary market-intelligence activity signals state interest in reshaping pharmaceutical procurement logistics and cost structures rather than soliciting carboquone itself as a finished pharmaceutical product.

The recent RFI represents exploratory procurement activity rather than a formal competitive solicitation with binding timelines, budget allocations, or award values. Texas HHS issued the RFI to inform future procurement strategy before publishing a formal RFP with established financial and temporal parameters. No other recent state or local opportunities under UNSPSC 51113301 appear in the current activity stream, suggesting limited direct procurement volume under this specific commodity code at this time. The code's narrow scope — a single chemical pharmaceutical — may concentrate actual purchasing within state pharmacy benefit programs and specialized vendor relationships not yet visible in publicly posted RFP or ITB activity. Business development professionals should monitor Texas HHS for subsequent RFP activity following this information-gathering phase and assess whether direct-to-manufacturer models expand to other state health agencies.